FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293984687> ?p ?o ?g. }

• W2293984687 endingPage "926" @default.
• W2293984687 startingPage "919" @default.
• W2293984687 abstract "Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) have been described as revolutionary. However, it remains uncertain how effective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV. Bridging this gap between efficacy and effectiveness requires a focus on the generalizability of clinical trials.Generalizability of DAA trials was assessed by applying the eligibility criteria from 5 efficacy trials: NCT01479868, PHOTON-1 (NCT01667731), TURQUOISE-I (NCT01939197), ION-4 (NCT02073656), and ALLY-2 (NCT02032888) that evaluated simeprevir; sofosbuvir; ombitasvir, paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respectively, to the Canadian Coinfection Cohort, representing approximately 23% of the total coinfected population in care in Canada.Of 874 active participants, 70% had chronic HCV, of whom 410, 26, 94, and 11 had genotypes 1, 2, 3, and 4, respectively. After applying trial eligibility criteria, only 5.9% (24/410) would have been eligible for enrollment in the simeprevir trial, 9.8% (52/530) in PHOTON-1, 6.3% (26/410) in TURQUOISE-I, and 8.1% (34/421) in ION-4. The ALLY-2 study was more inclusive; 43% (233/541) of the cohort would have been eligible. The most exclusive eligibility criteria across all trials with the exception of ALLY-2 were restriction to specific antiretroviral therapies (63%-79%) and active illicit drug use (53%-55%).DAA trial results may have limited generalizability, since the majority of coinfected individuals were not eligible to participate. Exclusions appeared to be related to improving treatment outcomes by not including those at higher risk of poor adherence and reinfection--individuals for whom real-world data are urgently needed." @default.
• W2293984687 created "2016-06-24" @default.
• W2293984687 creator A5000568574 @default.
• W2293984687 creator A5001045724 @default.
• W2293984687 creator A5002632928 @default.
• W2293984687 creator A5005263512 @default.
• W2293984687 creator A5006179595 @default.
• W2293984687 creator A5009499168 @default.
• W2293984687 creator A5020475843 @default.
• W2293984687 creator A5020509589 @default.
• W2293984687 creator A5023394537 @default.
• W2293984687 creator A5024639454 @default.
• W2293984687 creator A5026415367 @default.
• W2293984687 creator A5030638824 @default.
• W2293984687 creator A5034437717 @default.
• W2293984687 creator A5039463522 @default.
• W2293984687 creator A5047372053 @default.
• W2293984687 creator A5048550846 @default.
• W2293984687 creator A5051500672 @default.
• W2293984687 creator A5061614395 @default.
• W2293984687 creator A5061991540 @default.
• W2293984687 creator A5066810153 @default.
• W2293984687 creator A5073852786 @default.
• W2293984687 creator A5074441717 @default.
• W2293984687 creator A5078545285 @default.
• W2293984687 creator A5079544085 @default.
• W2293984687 creator A5084248794 @default.
• W2293984687 creator A5085309738 @default.
• W2293984687 date "2016-01-06" @default.
• W2293984687 modified "2023-10-14" @default.
• W2293984687 title "How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?" @default.
• W2293984687 cites W1574174041 @default.
• W2293984687 cites W1621802947 @default.
• W2293984687 cites W1903580466 @default.
• W2293984687 cites W191695008 @default.
• W2293984687 cites W1973675889 @default.
• W2293984687 cites W1996434966 @default.
• W2293984687 cites W2002026671 @default.
• W2293984687 cites W2008562148 @default.
• W2293984687 cites W2011249435 @default.
• W2293984687 cites W2021874471 @default.
• W2293984687 cites W2047156711 @default.
• W2293984687 cites W2072462822 @default.
• W2293984687 cites W2078251659 @default.
• W2293984687 cites W2092646281 @default.
• W2293984687 cites W2096150523 @default.
• W2293984687 cites W2097405564 @default.
• W2293984687 cites W2101368910 @default.
• W2293984687 cites W2102831953 @default.
• W2293984687 cites W2106081736 @default.
• W2293984687 cites W2106777786 @default.
• W2293984687 cites W2113428683 @default.
• W2293984687 cites W2124509162 @default.
• W2293984687 cites W2142434090 @default.
• W2293984687 cites W2143244227 @default.
• W2293984687 cites W2161330753 @default.
• W2293984687 cites W2163373419 @default.
• W2293984687 cites W2164437680 @default.
• W2293984687 cites W2278700271 @default.
• W2293984687 cites W2332403844 @default.
• W2293984687 cites W2418854365 @default.
• W2293984687 cites W83931366 @default.
• W2293984687 doi "https://doi.org/10.1093/cid/civ1222" @default.
• W2293984687 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4787608" @default.
• W2293984687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26743093" @default.
• W2293984687 hasPublicationYear "2016" @default.
• W2293984687 type Work @default.
• W2293984687 sameAs 2293984687 @default.
• W2293984687 citedByCount "67" @default.
• W2293984687 countsByYear W22939846872016 @default.
• W2293984687 countsByYear W22939846872017 @default.
• W2293984687 countsByYear W22939846872018 @default.
• W2293984687 countsByYear W22939846872019 @default.
• W2293984687 countsByYear W22939846872020 @default.
• W2293984687 countsByYear W22939846872021 @default.
• W2293984687 countsByYear W22939846872022 @default.
• W2293984687 crossrefType "journal-article" @default.
• W2293984687 hasAuthorship W2293984687A5000568574 @default.
• W2293984687 hasAuthorship W2293984687A5001045724 @default.
• W2293984687 hasAuthorship W2293984687A5002632928 @default.
• W2293984687 hasAuthorship W2293984687A5005263512 @default.
• W2293984687 hasAuthorship W2293984687A5006179595 @default.
• W2293984687 hasAuthorship W2293984687A5009499168 @default.
• W2293984687 hasAuthorship W2293984687A5020475843 @default.
• W2293984687 hasAuthorship W2293984687A5020509589 @default.
• W2293984687 hasAuthorship W2293984687A5023394537 @default.
• W2293984687 hasAuthorship W2293984687A5024639454 @default.
• W2293984687 hasAuthorship W2293984687A5026415367 @default.
• W2293984687 hasAuthorship W2293984687A5030638824 @default.
• W2293984687 hasAuthorship W2293984687A5034437717 @default.
• W2293984687 hasAuthorship W2293984687A5039463522 @default.
• W2293984687 hasAuthorship W2293984687A5047372053 @default.
• W2293984687 hasAuthorship W2293984687A5048550846 @default.
• W2293984687 hasAuthorship W2293984687A5051500672 @default.
• W2293984687 hasAuthorship W2293984687A5061614395 @default.
• W2293984687 hasAuthorship W2293984687A5061991540 @default.
• W2293984687 hasAuthorship W2293984687A5066810153 @default.
• W2293984687 hasAuthorship W2293984687A5073852786 @default.

• next